Group 1 - Citi updated its valuation model for Universal Medical following the release of its first-half results, raising the earnings per share forecasts for 2025, 2026, and 2027 by 4%, 6%, and 4% respectively, reflecting a decrease in financing costs and an expansion in the net present value of the financing lease business [1] - The target price for Universal Medical was increased from HKD 6.3 to HKD 6.9, with a "Buy" rating assigned [1]

2025 中期報告 目 錄 公司資料 2 定義 4 公司簡介 7 業績概覽 8 管理層討論與分析 10 權益披露 64 企業管治 67 其他資料 69 簡明綜合中期財務資料的審閱報告 74 簡明中期合併利潤表 76 簡明中期合併綜合收益表 77 簡明中期合併財務狀況表 78 簡明中期合併權益變動表 80 簡明中期合併現金流量表 82 簡明綜合中期財務資料附註 85 公司資料 (1) 於2025年7月25日辭任 董事會 主席及副主席 陳仕俗先生 （主席） 陳啟剛先生 （副主席） (1) 執行董事 陳仕俗先生 王文兵先生 （首席執行官） 王琳女士 非執行董事 陳啟剛先生(1) 童朝銀先生 林春海先生(2) 朱梓陽先生 徐明先生(3) 獨立非執行董事 李引泉先生 鄒小磊先生 許志明先生 陳曉峰先生 審核委員會 李引泉先生 （主席） 鄒小磊先生 童朝銀先生 薪酬委員會 鄒小磊先生 （主席） 陳啟剛先生(1) 林春海先生(2) 李引泉先生 許志明先生 徐明先生(3) 提名委員會 陳仕俗先生 （主席） 王琳女士(2) 李引泉先生 鄒小磊先生 陳曉峰先生 徐明先生(3) 戰略與ESG委員會 陳仕俗先生 （主席） 陳啟剛先生 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 通用環球醫療集團有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 不適用 備註： 因公司註冊成立於香港，故法定股本及註冊股本的概念並不適用。 FF301 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02666 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,891,539,661 | | 0 | | 1,891,539,661 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1,891,539,661 | | 0 | | ...

Group 1 - The core viewpoint of the article highlights that Global Medical (02666.HK) reported a revenue of 7.581 billion yuan for the first half of 2025, representing a year-on-year growth of 15.9% [1] - The net profit for the same period was 1.335 billion yuan, with a year-on-year increase of 6.6%, while the profit attributable to shareholders was 1.228 billion yuan, up by 8% [1] - The company operates 68 medical institutions, focusing on comprehensive and specialized healthcare services, as well as health technology and financial solutions [1] Group 2 - The comprehensive medical segment contributed 4.22 billion yuan in revenue, a 15.8% increase year-on-year, despite a decline in profit due to lower medical insurance payment rates and increased costs from new projects [1] - The total number of treatments conducted at the 65 consolidated medical institutions was approximately 5.09 million, reflecting a 2.8% increase year-on-year, with surgical procedures reaching 53,000, up by 3% [1] - The specialized medical business is expanding, with significant developments in ophthalmology and oncology, including partnerships and new hospital constructions [2] Group 3 - The equipment lifecycle management business generated 418 million yuan in revenue, a substantial year-on-year growth of 58.7%, with a profit of 48.1 million yuan, increasing by 45.9% [2] - The company is enhancing operational efficiency and management levels of medical equipment, contributing to cost reduction and quality improvement for hospitals [2]

Core Viewpoint - Global Medical (02666) reported a strong performance in its mid-year results for 2025, showcasing significant revenue growth and profitability, which positively influenced its stock price [1] Financial Performance - The company achieved a revenue of RMB 7.581 billion, representing a year-on-year increase of 15.9% [1] - The profit attributable to ordinary shareholders was approximately RMB 1.228 billion, reflecting a growth of 8% compared to the previous year [1] - Basic earnings per share stood at RMB 0.65 [1] Business Operations - As of June 30, 2025, the company operated 68 comprehensive and specialized medical institutions, providing quality medical services to the public [1] - The company is engaged in full-cycle management of medical equipment and health technology businesses, including smart health and wellness services [1] - It offers comprehensive financial solutions centered around financing leasing for its clients [1]

Core Viewpoint - Universal Medical (02666) reported a strong performance in its mid-2025 results, showing significant growth in revenue and profit, which positively impacted its stock price [1] Financial Performance - The company reported a revenue of RMB 7.581 billion, representing a year-on-year increase of 15.9% [1] - The profit attributable to ordinary shareholders was approximately RMB 1.228 billion, reflecting a year-on-year growth of 8% [1] - Basic earnings per share were reported at RMB 0.65 [1] Business Operations - As of June 30, 2025, the company operated 68 comprehensive and specialized medical institutions, providing quality medical services to the public [1] - The company is involved in full-cycle management of medical equipment, smart health technology, and offers comprehensive financial solutions centered around financing leasing [1]

Core Insights - The company reported a revenue of approximately RMB 7,580.7 million for the six months ending June 30, 2025, representing a 15.9% increase compared to approximately RMB 6,542.7 million for the same period in 2024 [1] - The profit attributable to ordinary shareholders for the same period was approximately RMB 1,228.1 million, an 8.0% increase from approximately RMB 1,137.2 million in 2024 [1] Financial Performance - Total assets as of June 30, 2025, were approximately RMB 85,716.6 million, a decrease of 0.4% from approximately RMB 86,032.3 million as of December 31, 2024 [1] - Equity attributable to ordinary shareholders was approximately RMB 17,703.4 million as of June 30, 2025, reflecting a 3.1% increase from approximately RMB 17,175.7 million as of December 31, 2024 [1] - Return on equity for the six months ending June 30, 2025, was 14.08% [1] - Return on total assets for the same period was 3.11% [1]

Core Insights - The company reported a revenue of RMB 7.581 billion for the six months ending June 30, 2025, representing a year-on-year growth of 15.9% [1] - The profit attributable to ordinary shareholders was approximately RMB 1.228 billion, reflecting an 8% increase compared to the previous period [1] - Basic earnings per share stood at RMB 0.65 [1] Business Operations - As of June 30, 2025, the company operated 68 comprehensive and specialized medical institutions, providing quality medical services to the public [1] - The company engaged in full-cycle management of medical equipment and health technology businesses, including smart health and wellness services [1] - It offered comprehensive financial solutions centered around financing leasing for its clients [1]

Core Viewpoint - The company, Universal Medical (02666), reported a revenue of RMB 7.581 billion for the six months ending June 30, 2025, representing a year-on-year growth of 15.9% [1] - The profit attributable to ordinary shareholders was approximately RMB 1.228 billion, reflecting an 8% increase compared to the previous year [1] - Basic earnings per share were reported at RMB 0.65 [1] Group 1 - The company operates 68 comprehensive and specialized medical institutions, providing quality medical services to the public [1] - The company is engaged in full-cycle management of medical equipment and health technology businesses, including smart health and wellness services [1] - The company offers comprehensive financial solutions centered around financing leasing for its clients [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：2666） 截至2025年6月30日止六個月的中期業績 財務摘要 1 • 截至2025年6月30日止六個月，收入約人民幣7,580.7百萬元，較2024年同期的約 人民幣6,542.7百萬元增長15.9%。 • 截至2025年6月30日止六個月，期內溢利約人民幣1,335.2百萬元，較2024年同期 的約人民幣1,252.2百萬元增長6.6%。 • 截至2025年6月30日止六個月，本公司普通股權益持有人應佔期內溢利約人民幣 1,228.1百萬元，較2024年同期的約人民幣1,137.2百萬元增長8.0%。 • 於2025年6月30日，總資產約人民幣85,716.6百萬元，較於2024年12月31日的約 人民幣86,032.3百萬元減少0. ...